openPR Logo
Press release

Myopia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics

02-26-2024 12:22 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Myopia Pipeline Assessment Covering Clinical Trials, Emerging

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Myopia Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myopia Therapeutics Market.

The report provides a detailed description of the Myopia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Myopia Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myopia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Myopia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Myopia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myopia treatment market.

Learn More about the Clinical and Commercial Development Activities in the Myopia Therapeutics Domain @
https://www.delveinsight.com/report-store/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myopia Therapeutics Analysis
Around 8+ prominent companies are actively engaged in the development of therapies for Myopia. Among these, Sydnexis stands out for advancing its Myopia drug candidates to the most advanced stage of clinical trials, specifically Phase III. This pivotal phase marks a critical milestone in the drug development journey, where the effectiveness and safety of the treatment are thoroughly evaluated in a larger patient population. Sydnexis's progress to Phase III underscores the potential significance of their therapeutic approach in addressing the challenges associated with Myopia, reflecting dedication and advancement within the field of ophthalmology and vision care.

Myopia Companies in the Therapeutics Market Include:
• Sydnexis
• Sunhawk Vision Biotech
• Vyluma
• Eyenovia
• Cloudbreak Therapeutics
• Stuart Therapeutics
And Many Others

Emerging and Marketed Myopia Therapies Covered in the Report Include:
• SYD-101: Sydnexis
• MicroPine: Eyenovia
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Myopia Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Myopia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Myopia Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Myopia Current Treatment Patterns
4. Myopia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myopia Late-Stage Products (Phase-III)
7. Myopia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myopia Discontinued Products
13. Myopia Product Profiles
14. Myopia Companies
15. Myopia Drugs
16. Dormant and Discontinued Products
17. Myopia Unmet Needs
18. Myopia Future Perspectives
19. Myopia Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myopia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics here

News-ID: 3399292 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Myopia

Myopia Control Lenses Market Forecast to Expand at 16.2% CAGR Amid Increasing Pe …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Myopia Control Lenses Market- (By Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-Focus Lenses, Peripheral Defocus Lenses), By Age Group (Children, Adults), By Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the latest research by InsightAce Analytic, the Global Myopia Control Lenses Market is valued
Myopia Control Lenses Market Size to Grow with Rising Prevalence of Childhood My …
The latest Myopia Control Lenses Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its
Latest Trends In Myopia Treatment Devices Market
A cutting-edge solution to the problem of myopia or nearsightedness is a wearable gadget for myopia control. These tools, which frequently come in the shape of smart glasses or specialised contact lenses, make use of cutting-edge technology to control and slow the growth of myopia. Wearable myopia control devices offer a proactive method of maintaining eye health by utilising features like changeable focus, customised vision correction, and real-time monitoring. Request
Myopia Control Devices Market - Seeing Beyond Blur: Revolutionary Myopia Devices …
Newark, New Castle, USA: The "Myopia Control Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Myopia Control Devices Market: https://www.growthplusreports.com/report/myopia-control-devices-market/7989 This latest report researches the industry structure,
Myopia Control Devices Market - Unlocking the Future of Clear Sight: Myopia Cont …
Newark, New Castle, USA - new report, titled Myopia Control Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Myopia Control Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Myopia Control Devices market. The report offers an overview of
The Myopia Market is expected to be driven by the factors such as the rising cas …
The Myopia market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions. The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to